The study will be an open label cohort study with 2 two-treatment groups 2). Both groups will
be treated with a single oral administration of Diethylcarbamazine (DEC) 6 mg/kg +
Albendazole (ALB) 400 mg + Ivermectin (IVR) 200 µg/kg (IDA). One treatment group will include
men and women with W. bancrofti infections (>50 Mf/ml, N=30). The other treatment group will
include men and women who are free of W. bancrofti infection based on negative blood tests
for both microfilariae (Mf) and circulating filarial antigen (N=30). Active follow-up for
adverse events (AE) will be for 72hrs and passive follow-up for 7 days following treatment.
Participants will be followed again at 1 year to evaluate treatment efficacy. Individuals
with severe AEs (grade 3 or higher) will be transported to the Agboville District Hospital
and cared for by the hospital staff. Based on treatment of over 100 Lymphatic filariasis (LF)
infected individuals any AEs develop within the first 72 hours following treatment and
uncommonly up to 7 days post-treatment.
All individuals will be admitted to a single health center or hospital in Côte d'Ivoire.
Subjects will be monitored for 72-hours after treatment for safety and to facilitate sampling
for drug analyses and safety tests. Participants will undergo clinical monitoring every 6
hours to evaluate potential adverse effects of Ivermectin + Diethylcarbamazine + Albendazole
(IDA) treatment. Participants will also be monitored for hematologic, or biochemical
abnormalities during the period of observation.